Our finding that glucagon administration does not affect reproductive hormones in healthy men provides important data on potential off-target effects in the ongoing development of glucagon receptor agonists for the treatment of obesity. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.